Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase biomarker development framework
Published inEuropean journal of nuclear medicine and molecular imaging, vol. 48, no. 7, p. 2097-2109
Publication date2021-07
First online date2021-02-06
Abstract
Keywords
- Alzheimer’s disease
- Biomarker-based diagnosis
- PET
- Strategic roadmap
- [18F]flortaucipir
- Alzheimer Disease / diagnostic imaging
- Biomarkers
- Carbolines
- Humans
- Positron-Emission Tomography
- Tau Proteins
Affiliation entities
Funding
- FNS - IZSEZo [188355]
Citation (ISO format)
WOLTERS, E E et al. Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase biomarker development framework. In: European journal of nuclear medicine and molecular imaging, 2021, vol. 48, n° 7, p. 2097–2109. doi: 10.1007/s00259-020-05118-w
Main files (1)
Article (Published version)
Secondary files (1)
Identifiers
- PID : unige:160864
- DOI : 10.1007/s00259-020-05118-w
- PMID : 33547556
- PMCID : PMC8175307
ISSN of the journal1619-7070